The effect of metallic magnesium degradation products on osteoclast-induced osteolysis and attenuation of NF-κB and NFATc1 signaling

Biomaterials

Volumn 35, Issue 24, 2014, Pages 6299-6310

  Zhai, Zanjing ^a   Qu, Xinhua ^a   Li, Haowei ^a   Yang, Ke ^b   Wan, Peng ^b   Tan, Lili ^b   Ouyang, Zhengxiao ^a,c   Liu, Xuqiang ^a   Tian, Bo ^a   Xiao, Fei ^a   Wang, Wengang ^a   Jiang, Chuan ^a   Tang, Tingting ^a   Fan, Qiming ^a   Qin, An ^a   Dai, Kerong ^a,d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b INSTITUTE OF METAL RESEARCH   (China)

^c Central South University   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Magnesium; NF B; NFATc1; Osteoclast; Osteolysis

Indexed keywords

ARTHROPLASTY; DEGRADATION; PROSTHETICS;

DEGRADATION PRODUCTS; NFATC1; NUCLEAR TRANSLOCATIONS; OSTEOCLAST; OSTEOCLAST FORMATION; OSTEOLYSIS; PROSTHETIC LOOSENING; TOTAL JOINT ARTHROPLASTY;

MAGNESIUM;

ACTIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAGNESIUM; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT;

ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; BONE DEVELOPMENT; C57BL MOUSE; CELL DEATH; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; PH; SIGNAL TRANSDUCTION; SKULL; TIME;

ACTINS; ANIMALS; CELL DEATH; CELL LINE; CYTOKINES; GENE EXPRESSION REGULATION; HYDROGEN-ION CONCENTRATION; MAGNESIUM; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOGENESIS; OSTEOLYSIS; RANK LIGAND; SIGNAL TRANSDUCTION; SKULL; TIME FACTORS;

EID: 84901402163     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.044     Document Type: Article

References (46)

1. Harris W.H. Wear and periprosthetic osteolysis: the problem. Clin Orthop Relat Res 2001, 393:66-70.
2. Tsutsumi R., Hock C., Bechtold C.D., Proulx S.T., Bukata S.V., Ito H., et al. Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. JOrthop Res 2008, 26:1340-1346.
3. Kyomoto M., Moro T., Saiga K., Hashimoto M., Ito H., Kawaguchi H., et al. Biomimetic hydration lubrication with various polyelectrolyte layers on cross-linked polyethylene orthopedic bearing materials. Biomaterials 2012, 33:4451-4459.
4. Jacobs C.A., Christensen C.P., Greenwald A.S., McKellop H. Clinical performance of highly cross-linked polyethylenes in total hip arthroplasty. JBone Joint Surg Am 2007, 89:2779-2786.
5. Huo M.H., Stockton K.G., Mont M.A., Bucholz R.W. What's new in total hip arthroplasty. JBone Joint Surg Am 2012, 94:1721-1727.
6. Roato I., Caldo D., D'Amico L., D'Amelio P., Godio L., Patanè S., et al. Osteoclastogenesis in peripheral blood mononuclear cell cultures of periprosthetic osteolysis patients and the phenotype of T cells localized in periprosthetic tissues. Biomaterials 2010, 31:7519-7525.
7. Ingham E., Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials 2005, 26:1271-1286.
8. Goodman S.B., Ma T., Chiu R., Ramachandran R., Lane Smith R. Effects of orthopaedic wear particles on osteoprogenitor cells. Biomaterials 2006, 27:6096-6101.
9. Holding C.A., Findlay D.M., Stamenkov R., Neale S.D., Lucas H., Dharmapatni A., et al. The correlation of RANK, RANKL and TNFα expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 2006, 27:5212-5219.
10. Rakshit D.S., Ly K., Sengupta T.K., Nestor B.J., Sculco T.P., Ivashkiv L.B., et al. Wear debris inhibition of anti-osteoclastogenic signaling by Interleukin-6 and interferon-γMechanistic insights and implications for periprosthetic osteolysis. JBone Joint Surg Am 2006, 88:788-799.
11. Crotti T.N., Smith M.D., Findlay D.M., Zreiqat H., Ahern M.J., Weedon H., et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFκB, RANK ligand and osteoprotegerin. Biomaterials 2004, 25:565-573.
12. Clohisy J.C., Frazier E., Hirayama T., Abu-Amer Y. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. JOrthop Res 2003, 21:202-212.
13. Bhandari M., Bajammal S., Guyatt G.H., Griffith L., Busse J.W., Schünemann H., et al. Effect of bisphosphonates on periprosthetic bone Mineral density after total joint ArthroplastyA meta-analysis. JBone Joint Surg Am 2005, 87:293-301.
14. Peichl P., Griesmacher A., Kumpan W., Schedl R., Prosquil E., Bröll H. Clinical outcome of salmon calcitonin nasal spray treatment in postmenopausal women after total hip arthroplasty. Gerontology 2005, 51:242-252.
15. Ren W., Wu B., Peng X., Mayton L., Yu D., Ren J., et al. Erythromycin inhibits wear debris-induced inflammatory osteolysis in a murine model. JOrthop Res 2006, 24:280-290.
16. Cohen S., McClung M., Lewiecki E., Bolognese M., Woodson G., Moffett A., et al. AMG 162 administered every 6 months causes rapid and sustained decreases in bone turnover in postmenopausal women with low bone mineral density (BMD). Arthritis Rheum 2004, 50:438-439.
17. Looney R.J., Schwarz E.M., Boyd A., O'Keefe R.J. Periprosthetic osteolysis: an immunologist's update. Curr Opin Rheumatol 2006, 18:80-87.
18. McBRIDE E.D. Absorbable metal in bone surgery: a further report on the use of magnesium alloys. JAMA 1938, 111:2464-2467.
19. Li Z., Gu X., Lou S., Zheng Y. The development of binary Mg-Ca alloys for use as biodegradable materials within bone. Biomaterials 2008, 29:1329-1344.
20. Staiger M.P., Pietak A.M., Huadmai J., Dias G. Magnesium and its alloys as orthopedic biomaterials: a review. Biomaterials 2006, 27:1728-1734.
21. Troitskii V., Tsitrin D. The resorbing metallic alloy 'Osteosinthezit'as material for fastening broken bone. Khirurgiia 1944, 8:41-44.
22. Znamenskii M. Metallic osteosynthesis by means of an apparatus made of resorbing metal. Khirurgiia 1945, 12:60-63.
23. 3 Ap-collagen composite in promoting bone formation. Biomaterials 2003, 24:4913-4920.
24. Belluci M.M., Giro G., del Barrio R.A.L., Pereira R.M.R., Marcantonio E., Orrico S.R.P. Effects of magnesium intake deficiency on bone metabolism and bone tissue around osseointegrated implants. Clin Oral Implants Res 2011, 22:716-721.
25. Rude R.K., Kirchen M.E., Gruber H.E., Stasky A.A., Meyer M.H. Magnesium deficiency induces bone loss in the rat. Miner Electrolyte Metab 1998, 24:314-320.
26. Stending-Lindberg G., Tepper R., Leichter I. Trabecular bone density in a two year controlled trial of peroral magnesium in osteoporosis. Magnes Res 1993, 6:155-163.
27. Dimai H.-P., Porta S., Wirnsberger G., Lindschinger M., Pamperl I., Dobnig H., et al. Daily oral magnesium supplementation suppresses bone turnover in young adult males. JClin Endocrinol Metab 1998, 83:2742-2748.
28. Qin A., Cheng T.S., Lin Z., Cao L., Chim S.M., Pavlos N.J., et al. Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor saliphenylhalamide through inhibition of osteoclast bone resorption. PloS One 2012, 7:e34132.
29. Zhai Z., Qu X., Yan W., Li H., Liu G., Liu X., et al. Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling. Breast Cancer Res Treat 2014, 1-13.
30. Zhai Z., Li H., Liu G., Qu X., Tian B., Yan W., et al. Andrographolide suppresses RANKL-induced osteoclastogenesis invitro and prevents inflammatory bone loss invivo. Br J Pharmacol 2014, 171:663-675.
31. Wang C., Steer J.H., Joyce D.A., Yip K.H.M., Zheng M.H., Xu J. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-Induced NF-κB activation. JBone Miner Res 2003, 18:2159-2168.
32. Qin A., Cheng T.S., Lin Z., Pavlos N.J., Jiang Q., Xu J., et al. Versatile roles of V-ATPases accessory subunit Ac45 in osteoclast formation and function. PloS One 2011, 6:e27155.
33. Qin A., Cheng T., Pavlos N., Lin Z., Dai K., Zheng M. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption. Int J Biochem Cell Biol 2012, 44(9):1422-1435.
34. Wilson S.R., Peters C., Saftig P., Brömme D. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. JBiol Chem 2009, 284:2584-2592.
35. Asagiri M., Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007, 40:251-264.
36. Holt G., Murnaghan C., Reilly J., Meek R. The biology of aseptic osteolysis. Clin Orthop Relat Res 2007, 460:240-252.
37. Sundfeldt M., V Carlsson L., B Johansson C., Thomsen P., Gretzer C. Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthop 2006, 77:177-197.
38. Purdue P.E., Koulouvaris P., Potter H.G., Nestor B.J., Sculco T.P. The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res 2007, 454:251-261.
39. Waddell J., Pritzker K.P., Boynton E.L. Increased cytokine secretion in patients with failed implants compared with patients with primary implants. Clin Orthop Relat Res 2005, 434:170-176.
40. Rude R.K., Singer F.R., Gruber H.E. Skeletal and hormonal effects of magnesium deficiency. JAm Coll Nutr 2009, 28:131-141.
41. Rude R.K., Gruber H.E. Magnesium deficiency and osteoporosis: animal and human observations. JNutr Biochem 2004, 15:710-716.
42. Schwartz R., Reddi A. Influence of magnesium depletion on matrix-induced endochondral bone formation. Calcif Tissue Int 1979, 29:15-20.
43. Rochelson B., Dowling O., Schwartz N., Metz C.N. Magnesium sulfate suppresses inflammatory responses by human umbilical vein endothelial cells (HuVECs) through the NFκB pathway. JReprod Immunol 2007, 73:101-107.
44. Zhao Q., Wang X., Liu Y., He A., Jia R. NFATc1: functions in osteoclasts. Int J Biochem Cell Biol 2010, 42:576-579.
45. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. JExp Med 2005, 202:1261-1269.
46. 2+. Am J Physiol Lung Cell Mol Physiol 1996, 271:L251-L257.